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Abstract
Background: Despite education and availability of drugs and vaccines, hepatitis B virus (HBV) is still the most
common severe liver infection in the world accounting for >1 million annual deaths worldwide. Transfusion of
infected blood, unprotected sex and mother to child transmission are 3 key transmission routes of HBV in Ghana.
There is high incidence of blood demanding health situations in northern Ghana resulting from anemia, accidents,
malnutrition, etc. The higher the demand, the higher the possibility of transmitting HBV through infected blood.
The aim of the investigation was to estimate the prevalence of HBV in blood donors which will provide
justification for interventions that will help minimize or eliminate HBV infection in Ghana.
Findings: We investigated the prevalence of HBV infection among blood donors at Tamale Teaching Hospital. The
Wondfo HBsAg test kit was used to determine the concentration of HBsAg in 6,462 (576 voluntary and 5,878
replacement) donors as being ≥1 ng/ml. 10.79% of voluntary donors and 11.59% of replacement donors were
HBsAg+. The 20-29 year group of voluntary donors was >2 times more likely to be HBsAg + than 40-60. Also the
20-29 year category of replacement donors was >4 times as likely to be HBsAg + than 50-69.
Conclusions: Risk of infection was age, sex and donor type dependent. The 20-29 year category had the highest
prevalence of HBsAg + cases, mostly males residing within the metropolis.
Introduction
Hepatitis B virus (HBV) infection is associated with a
wide variety of clinical manifestations including jaun-
dice, hepatomegaly, anorexia, abdominal and gastric dis-
comfort, etc. [1,2]. First discovered in 1967, HBV of the
Hapadnaviridae family is a human blood-borne virus
which is strictly hepatotropic [3-5]. HBV genotypes [6,7]
have a distinct geographical distribution with genotypes
A and D predominant in Europe, Middle East, Central
Asia, Siberia and America. Genotypes B and C are pre-
dominant in East Asia while genotype E is more predo-
minant in Africa [8]. Genotype F has been reported in
Central America. Also, genotype G has been reported in
the United States and France [9].
Hepatitis B is a major cause of liver disease worldwide
[10]. Despite education, campaigns and availability of
effective drugs e.g. interferon alpha, lamivudine, adefovir
[11] and vaccines [12], the disease is still a major global
health problem. There is serologic evidence of past or
present HBV infection of approximately 2 billion people
[13,14].
Hepatitis B is a contagious disease. Transfusion -
transmitted HBV infection has become a major mode
of transmission of HBV in high prevalence areas in
sub Saharan Africa [15]. Transfusion of infected blood
and unprotected sex are two key transmission routes
of HBV in Ghana. Indeed, the WHO has documented
that between 5 and 10% of HIV infections worldwide
are transmitted through the transfusion of contami-
nated blood and blood products [16]. Thus, indicating
that many more recipients of blood products are
infected by HBV, HCV, syphilis and many other infec-
tious agents [16]. The WHO has estimated that ≤50%
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of blood supply in sub-Saharan Africa is screened for
HBsAg due to lack of perceived utility and/or lack of
funds [17].
Blood safety therefore remains an issue of major
concern in transfusion medicine in Sub Saharan Africa
[15]. There is high incidence of blood-demanding
health situations in northern Ghana resulting from
anemia, malnutrition, accidents, surgical and obstetri-
cal emergencies associated with blood loss, etc. The
higher the demand for blood transfusion services, the
higher the possibility of transmitting HBV and other
blood-borne pathogens through contaminated blood.
Illiteracy, lack of adequate health information, low
socioeconomic situation in the region, inadequate
trained health personnel and some inappropriate cul-
tural practices linked with transmission dynamics
including polygamy tend to augment the disease trans-
mission. Furthermore, the National blood transfusion
service’s agenda, Government policies as well as that of
championing stake holders to combat the disease are
not clearly known. The study therefore was conducted
to determine the prevalence of hepatitis B infection
among blood donors at Tamale Teaching Hospital
Blood Bank which will indicate the risk of transfusing
infected blood if the blood is not properly screened.
The investigation will provide justification for re-stra-
tegizing and initiating more sensitive interventions that
will help minimize or possibly eliminate hepatitis B
infection in Ghana.
Methods
Study population
The study samples included all individuals who donated
blood from 01 January to 31 December, 2009. The study
recruited 6,462 individuals in two categories; 5,878
blood replacement donors (individuals called upon to
donate blood to patients) and 584 voluntary donors
(individuals who willingly donated blood to the blood
bank). Donor consent was obtained and confidentiality
guaranteed. Clearance was also obtained from the Regio-
nal Health Directorate to use the data for the purpose of
research only.
Collection and preparation of specimen
A 5cc syringe and needle were used to bleed approxi-
mately 5 ml of blood from each donor, transferred into
a vacutainer and centrifuged at 1500 rpm for 3 min to
obtain serum. The Wondfo One Step Cassette Style
HBsAg test kit (Guangzhou Wondfo Biotech Co. Ltd,
China) was used to determine the concentration of
HBsAg as being ≥1 ng/ml. A test strip was immersed in
each serum. The strips were removed after 10 sec and
placed on a dry clean non-absorbent table surface for 15
min after which they were visualized.
Interpretation of results
Negative test for HBV: Only one colored band appears
on the control (C) region. Positive test for HBV: In
addition to a pink colored control (C) band, a distinct
pink colored band also appears in the test (T) region.
Invalid test for HBV: A total absence of color in both
regions. Also, results of recruits who could not tell their
ages were eliminated.
Analysis of data
The data obtained was double entered into a spread
sheet. Descriptive analysis involved a display of sum-
mary statistics and cross tabulation of HBV, age groups
and gender. We generated a binary logistic variable (as
our primary dependent variable) to represent the status
of HBV infection coded 0/1. The prevalence was then
estimated as the proportion with infection alongside the
exact binomial confidence interval. The statistical differ-
ences within age groups and between genders were
tested with Pearson’s chi square as well as bivariate
logistic regression. A logistic regression was further used
to identify the independent associations between the
categories and the respective probability of HBV infec-
tion among individuals at the time of blood donation.
The data was analyzed using Stata version 11.2 (Spe-
cial Edition, College Station, Texas 77845 USA) statisti-
cal package set at 95% Confidence Interval (and a p-
value < 0.05 as considered statistically significant).
Results
Voluntary blood donors and HBV test results
Out of 584 voluntary donors, 2.05% were female. The
remaining 97.95% were male. Test results of 8 voluntary
donors were excluded because their ages could not be
determined. Of the remaining 576 voluntary donors,
10.79% tested positive for HBsAg (Table 1). Rather than
expected, fewer females (12) willingly donated blood
than males (572) of which 1 (8.33%) female was HBsAg
+ as against 62 (10.84%) males (Table 2). The age group
with the highest number of donors (53.47%) was 20-29
years which also constituted the highest number of posi-
tive cases (69.35% of all positive cases) among voluntary
donors (Table 3). Only 26 donors were between 40 and
60 years constituting the group with the least voluntary
donors. No donor between 40 and 60 years was diag-
nosed HBsAg + (Table 3).
In a further analysis of a logistic regression model
(Table 4), it was observed that, compared to the oldest
age category for voluntary blood donors (i.e. 40-60
years), the youngest age category, 11-19 years, were 1.4
times as likely to be HBsAg+. However, the largest age
category (20-29 years) were more than 2 times more
likely to be HBsAg + (OR: 2.13; p = 0.009; 95%C.I.
1.2063-3.7488).
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Replacement blood donors and HBV test results
Out of the 5,878 replacement donors including only 6
(0.1%) females, 33 recruits were excluded because their
ages could not be determined (Table 1). Of the remain-
ing 5,845 recruits, 11.59% were HBsAg+. As in volunteer
blood donors, the age group with the highest number of
donors (49.22%) was 20-29 years. Only 77 recruits
between ages of 50 and 69 years donated blood (Table
1). Generally, male donors were also more than female
donors through all age groups (Table 1).
None of the 6 female replacement donors was diag-
nosed with HBV. All the 11.59% of total blood replace-
ment recruits who were positive were males (Table 2).
Most positive cases (60.03%) were between 20 and 29
years followed by the 30-39 year age group with 28.02%
of all positive cases. The 50-69 year age group recorded
the least number of recruits likewise the least number of
HBsAg + cases (Table 3).
When compared to the oldest category of replacement
blood donors (50-69 years), the younger age groups 11-
19 and 20-29 years were more than 4 times as likely to
be HBsAg + (OR: 4.04; p = 0.023; 95%C.I. 1.2118-
13.4702) and (OR: 4.06; p = 0.018; 95%C.I. 1.2754-
12.9532) respectively. Those aged between 40-49 were
almost twice as likely to be HBsAg+, whilst the 30-39
year old category were nearly 2½ times more likely to
be HBsAg + (Table 4).
There were generally more replacement donors com-
pared to voluntary donors. The difference in prevalence
between the two groups was not significant (Chi2 =
0.6117; p = 0.434)
Discussion
The liver is multifunctional. It is recognized to perform
500 functions including neutralization of toxins and
drugs. This renders liver damage by HBV and other
agents fatal.
Main findings
The One Step HBsAg Test is a qualitative immunoassay
that detects HBsAg in blood serum. Monoclonal and
polyclonal antibodies are employed to identify HBsAg
with a 1 ng/ml sensitivity. Nevertheless, the high
Table 2 Cross tabulation of diagnosed status by gender
of voluntary and replacement blood donors
HBV
Status
Female (%) Male (%) Total (%)
VBD RBD VBD RBD VBD RBD
Positive 1(8.33) 0(0) 62(10.84) 681(11.6) 63(10.79) 681(11.59)
Negative 11
(91.67)
6
(100)
510
(89.16)
5,191
(88.4)
521
(89.21)
5,197
(88.41)
Total 12(100) 6
(100)
572(100) 5,872
(100)
584(100) 5,878(100)
VBD Voluntary blood donors; RBD Replacement blood donors; Pearson chi2 for
VBD (1) = 0.0767; Pr = 0.782; Pearson chi2 for RBD (1) = 0.7870 P-value =
0.375
Table 3 Cross tabulation of HBV Status of voluntary and
replacement blood donors by age
Age*
(years)
HBV Positive
(%)
HBV Negative
(%)
Total (%)
VBD RBD VBD RBD VBD RBD
11-19 18
(29.03)
38(5.6) 117
(22.76)
232(4.49) 135
(23.44)
270(4.62)
20-29 43
(69.35)
407
(60.03)
265
(51.56)
2,470
(47.8)
308
(53.47)
2,877
(49.22)
30-39 1(1.61) 190
(28.02)
106
(20.62)
1,891
(36.6)
107
(18.58)
2,081
(35.6)
40-49 0(0) 40(5.9) 26(5.06) 500(9.68) 264.51) 540(9.24)
50-59 - 3(0.44) - 74(1.43) - 77(1.32)
Total 62(100) 678
(100)
514
(100)
5,167
(100)
576
(100)
5,845
(100)
VBD Voluntary blood donors; RBD Replacement blood donors; Pearson chi2 for
VBD (3) = 18.1044; P-value < 0.001; Pearson chi2 for RBD (4) = 45.9008 P-value
< 0.001
Table 4 Logistic regression of HBV status and age
categories of voluntary and replacement blood donors
Age
(years)
Voluntary blood donors Replacement blood donors
OR p-
value
95% C.I. OR p-
value
95% C.I.
50-69 - 1.00
40-49 1.00 1.97 0.266 0.5953 6.5411
30-39 0.06 0.006 0.0086 04604 2.48 0.126 0.7739 7.9368
20-29 2.13 0.009 1.2063 3.7488 4.06 0.018 1.2754 12.9532
11-19 1.39 0.273 0.7727 2.4938 4.04 0.023 1.2118 13.4702
OR Odds Ratio; C.I. Confidence Interval
Table 1 Age and Gender demographics of voluntary and
replacement blood donors
Age*
(years)
Female (%) Male (%) Total (%)
VBD RBD VBD RBD VBD RBD
11-19 10
(83.33)
1
(16.67)
125
(22.16)
269(4.61) 135
(23.44)
270(4.62)
20-29 1(8.33) 4
(66.67)
307
(54.43)
2,873
(49.2)
308
(53.47)
2,877
(49.22)
30-39 1(8.33) 0(0) 106
(18.79)
2,081
(35.64)
107
(18.58)
2,081
(35.6)
40-49 0(0) 1
(16.67)
26(4.61) 539(9.23) 26(4.51) 540(9.24)
50-69 - 0(0) - 77(1.32) - 77(1.32)
Total 12(100) 6(100) 564
(100)
5,839
(100)
576
(100)
5,845
(100)
VBD Voluntary blood donors; RBD Replacement blood donors; Pearson chi2 for
VBD (3) = 24.6740; P-value <0.001; Pearson chi2 for RBD (4) = 4.8347 P-value
= 0.305
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prevalence of HBV infection (Table 1) is in concordance
with some studies conducted in rural areas in develop-
ing countries where it is considered endemic [18-22]. By
using a HBsAg assay with a detection limit of 1 ng/ml,
the real prevalence of HBsAg carriers might even have
been underestimated. Current EIA assays are showing
sensitivity of <1 ng/ml. In addition, blood donors with
occult HBV infection will not be detected (HBV DNA
+/HBsAg-: ~1% in Ghanaian donors) [23].
Yet, the high prevalence obtained among blood donors
who visited the hospital suggests that few people
undergo immunization within the region. This is
because the cost of immunization and/or testing is not
within the means of the people. Most developing coun-
tries are facing multiple threats to the safety of blood
supply because the cost of HBsAg screening is borne by
the patients and their families who do not enjoy health
coverage [17]. Generally also, there is no prevention of
transmission between mother and child. High preva-
lence of HBsAg markers in donors who were >10 years
is consistent with the concept that most primary HBV
infections are transmitted either vertically or horizon-
tally before age 10. Although most new infections occur
among infants and young children, HBV-related morbid-
ity and mortality is not immediately apparent [24]. The
prevalence of HBsAg among women of childbearing age
in Ghana is 11.5% [24]. This may also explain why low
percentages of positive cases were >50 years. It is likely
that by age 50 years, most carriers in the general popu-
lation would have died. Low HBsAg detection in older
donors might also be due to well known continuous
decrease of HBsAg levels in chronic carriers over time.
Most probably, HBV infection occurred before the age
of 20 in these old donors. Even though there were more
replacement donors, compared to voluntary donors, the
difference in prevalence between the two groups was
not significant (Chi2 = 0.6117; p = 0.434).
The reason for the gender imbalance, i.e. more males
(6,444) than females (18), cannot be directly inferred
from this data; however, within the context of the study
area, more men than women are usually called to take
responsibilities in representing families. The males are
also more proactive and independent in decision mak-
ing and volunteering than females would have the
opportunity for. This probably explains the huge differ-
ence in gender. Illiteracy among the people in the
region as well as poor access to relevant health informa-
tion/education may also be a contributory factor to the
high prevalence of the disease. The region is among
those with the lowest school enrolment rate, highest
dropout rate and highest illiteracy rates in the country.
The disease is often attributed to supernatural or spiri-
tual factors and/or alcoholism. This region is also prone
to frequent ethnic conflicts which do not help the
situation for intervention. Some socio cultural practices
like polygamy may also enhance transmission particu-
larly when a spouse either happens to contract the HBV
elsewhere or a carrier who is apparently normal over
years. The relatively high prevalence of HBV infection
among the youth could be the result of risky lifestyles
consistent with studies attributing it to unprotected sex
[19,25-27].
Conclusion
The prevalence of HBV infection among replacement
and voluntary blood donors visiting Tamale Teaching
Hospital in 2009 was estimated as 11.59% and 10.79%
respectively. Both rates were high among blood donors
who represent a significant part of the population within
the metropolis. The probability of infection was found
to be age and sex dependant. Young replacement blood
donors, aged 20-29 years were 4 times as likely as older
fellows (50-70 years) to be HBsAg + (OR: 4.04; p =
0.023, 95% C.I.:1.2118-13,4702). Among voluntary
donors, the rates were lower. Compared to older donors
(40-60 years) the youth group (20-29 years) were twice
as likely to be HBsAg + (OR: 2.13; p = 0.009, 95% C.I;
1.2063-3.7488). Female donors were few to the order of
1: 358 male donors.
To reduce the aforementioned prevalence, it will be
necessary for the Regional Health Directorate and
NGOs to plan major HBV vaccination campaigns and
educate people about risk factors for infection and bene-
fits of immunization. It will also be necessary for the
Ghana Health Service to provide kits with higher sensi-
tivity (sensitivity of <1 ng/ml) in order to eliminate as
many false positives as possible.
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